Japan PM Ishiba to announce resignation by August end – Mainichi
Savara Inc. (NASDAQ:SVRA), a pharmaceutical company based in Austin, Texas, with a market capitalization of $513 million, held its annual meeting of stockholders on Thursday. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet, though its stock has declined over 36% in the past six months. During the meeting, the stockholders elected six directors to the company’s board. The elected directors are Matthew Pauls, Nevan Elam, Richard J. Hawkins (NASDAQ:HWKN), Joseph S. McCracken, David A. Ramsay, and An van Es-Johansson. Each director will serve until the next annual meeting or until their successors are duly elected and qualified.
In addition to the board elections, three key proposals were put to a vote. The first proposal, which sought to ratify the appointment of RSM US LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, received overwhelming support. It garnered 151,289,378 votes in favor, with only 28,827 votes against and 147,086 abstentions.
The second proposal, an advisory vote on the compensation of Savara’s named executives, also passed. It received 120,600,997 votes in favor, 3,297,958 votes against, and 137,189 abstentions. The third proposal, which was an advisory vote on the preferred frequency of holding an advisory vote on executive compensation, indicated a preference for an annual vote. The breakdown of votes was 122,922,938 for one year, 101,608 for two years, 298,734 for three years, and 712,864 abstentions.
These results were disclosed in a Securities and Exchange Commission (SEC) filing, which provides detailed information about the voting outcomes and the company’s governance decisions. Savara Inc. continues to trade on the Nasdaq Global Select Market under the ticker symbol SVRA. InvestingPro analysis indicates the company maintains a healthy current ratio of 14.9, though analysts do not expect profitability this year. Investors can access comprehensive analysis and 8 additional ProTips through the detailed Pro Research Report, which transforms complex financial data into actionable intelligence. The company’s next earnings report is scheduled for August 7, 2025.
In other recent news, Savara Inc. disclosed its first-quarter 2025 results and corporate updates, which included a Refusal to File (RTF) from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for Molbreevi. The FDA requested additional Chemistry, Manufacturing, and Controls (CMC) data, although no safety or efficacy concerns were raised. Analysts at Oppenheimer assumed coverage with an Outperform rating and a $5 price target, reflecting confidence in the potential commercial success of Molbreevi. Conversely, H.C. Wainwright downgraded Savara from Buy to Neutral, citing concerns over the company’s communications and interactions with the FDA. Guggenheim maintained a Buy rating but reduced the price target to $8.00, anticipating a delayed market launch for Molbreevi in early 2027. Evercore ISI also adjusted its price target to $2.00, maintaining an In Line rating, and projected a commercial launch in January 2027. Savara plans to resubmit the BLA in the fourth quarter of 2025, with a potential Prescription Drug User Fee Act (PDUFA) date in the third quarter of 2026. The company remains focused on addressing regulatory requirements and advancing its pipeline of therapies for rare respiratory diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.